Twist Bioscience Expects To Exit FY24 With Adjusted EBITDA Breakeven For Its Core (SynBio, NGS) Business In Q4; Fiscal Year End Cash Is Projected To Be $220M
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience anticipates achieving adjusted EBITDA breakeven for its core business (SynBio, NGS) in Q4 of FY24. The company also projects its fiscal year-end cash to be $220M.
August 04, 2023 | 3:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Twist Bioscience expects to reach EBITDA breakeven for its core business by Q4 FY24 and projects year-end cash to be $220M.
The news is directly related to Twist Bioscience's financial performance. Achieving EBITDA breakeven indicates that the company is managing its operating costs effectively, which is a positive sign for investors. The projected year-end cash of $220M also suggests a strong liquidity position. This could lead to a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100